Peptide Development Labs raises US$2.2M in placement tied to HYTN spinout
What's the deal? Peptide Development Labs Inc. (PDL) closed a non-brokered private placement for gross proceeds of roughly US$2.2M alongside the completion of a statutory plan of arrangement with HYTN Innovations Inc. The raise came through 6,000,000 units priced at US$0.37 each, with each unit carrying one share and half a warrant exercisable at US$0.55 for 24 months.
Why now? The financing closed concurrently with the arrangement, effective at 00:01 on November 17, 2026. Under the deal, HYTN shareholders received one new HYTN share plus 0.0556 of a PDL share for each existing share they held.
What's the endgame? PDL will use net proceeds to pursue development milestones laid out in HYTN's October 16 management circular. Those include qualification and product setup, engineering and validation, regulatory and clinical readiness, and formal clinical development.
Where it lists: The Canadian Securities ExchangeDealroom has a profile for this one. Try Dealroom → granted conditional acceptance on November 11. PDL expects to begin trading under the symbol "PEPT" on November 20, 2026, while new HYTN shares keep the "HYTN" ticker.
The signal: The spinout-plus-financing structure lets PDL arrive on the public market with fresh capital earmarked for clinical work, separating the peptide-development venture from its parent. Securities issued carry a statutory hold of four months and one day.
Read more: Business Insider
Image credit: Generated with Gemini